^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IRAK-4 inhibitor

    Related drugs:
    Apply
    Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (NCT06439836)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/18/2025
    Initiation :
    02/21/2025
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • CD68 • CRP
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • emavusertib (CA-4948)
    Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS) (C-906289-002) (NCT05308264)
    Phase 1/2
    Rigel Pharmaceuticals
    Recruiting
    Last update posted :
    01/16/2025
    Initiation :
    09/12/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    TNFA • CRP
    |
    Chr del(5q)
    |
    R289
    Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS (NCT04278768)
    Phase 1/2
    Curis, Inc.
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    07/06/2020
    Primary completion :
    04/01/2026
    Completion :
    04/01/2026
    FLT3 • SF3B1 • U2AF1
    |
    FLT3 mutation • SF3B1 mutation • U2AF1 mutation
    |
    Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)
    CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (NCT05187182)
    Phase 1
    Washington University School of Medicine
    Recruiting
    Last update posted :
    12/04/2023
    Initiation :
    06/02/2023
    Primary completion :
    09/30/2026
    Completion :
    06/30/2027
    HER-2
    |
    HER-2 positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • emavusertib (CA-4948)